Autor | Taburet, Anne-Marie | |
Autor | Sauvageon, Hélène | |
Autor | Grinsztejn, Beatriz | |
Autor | Assuied, Alex | |
Autor | Veloso, Valdiléa G. | |
Autor | Pilotto, José Henrique | |
Autor | Castro, Nathalie de | |
Autor | Grondin, Carine | |
Autor | Fagard, Catherine | |
Autor | Molina, Jean-Michel | |
Data de acesso | 2016-04-28T16:31:04Z | |
Data de disponibilização | 2016-04-28T16:31:04Z | |
Data do publicação | 2015 | |
Citação | TABURET, Anne-Marie et al. Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy. Clinical Infection Disease, v. 61, n. 8, p. 1328-1235, Oct. 2015. | pt_BR |
ISSN | 1058-4838 | |
URI | https://www.arca.fiocruz.br/handle/icict/14016 | |
Idioma | eng | pt_BR |
Editor | Oxford University Press | pt_BR |
Direito Autoral | restricted access | pt_BR |
Título | Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy | pt_BR |
Tipo do documento | Article | pt_BR |
DOI | 10.1093/cid/civ477 | |
Resumo em Inglês | Background: Rifampicin (RIF) induces UGT1A1, an enzyme involved in raltegravir (RAL) elimination, thereby potentially lowering RAL exposure. We examined the pharmacokinetics of RAL in human immunodeficiency virus (HIV)-infected patients on RIF-based antitubercular therapy in the French National Agency for HIV/AIDS and Viral Hepatitis Research 12 180 Reflate Tuberculosis trial.
Methods: Patients started RAL in combination with tenofovir disoproxil fumarate and lamivudine after initiation of RIF (10 mg/kg/day). In arm 1 (n = 21), they received 400 mg RAL twice daily; in arm 2 (n = 16), they received RAL 800 mg twice daily initially then 400 mg twice daily 4 weeks after RIF discontinuation. Pharmacokinetic sampling was performed over 12-hour periods, 4 weeks after initiation of RAL together with RIF (period 1), 4 weeks after RIF discontinuation (period 2), and after the RAL dose reduction in arm 2 (period 3). Results: In arm 1, the geometric mean ratio (GMR) between period 1 and period 2 was 0.94 (90% confidence interval [CI], .64-1.37) for the 12-hour area under the time-concentration curve (AUC0-12), and 0.69 (90% CI, .42-1.13) for the concentration at 12 hours (C12). In arm 2, the corresponding GMRs were 0.75 (90% CI, .48-1.17) and 1.10 (90% CI, .61-2.00) for period 1 vs period 2, and 1.10 (90% CI, .78-1.55) and 1.68 (90% CI, .88-3.23) for period 1 vs period 3. Conclusions: The double dose of RAL overcompensated for RIF induction, but the standard dose was associated with only small decreases in AUC0-12 and C12 during RIF coadministration, warranting further evaluation in patients with HIV/tuberculosis coinfection. | pt_BR |
Afiliação | Hospital Bicetre, Assistance Publique-Hôpitaux de Paris. DHU Hepatinov; INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Sud, Kremlin Bicêtre. Paris, France. | pt_BR |
Afiliação | Hospital Saint-Louis. Assistance Publique-Hôpitaux de Paris. Paris, France. | pt_BR |
Afiliação | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Afiliação | Université de Bordeaux. Centre INSERM U897-Epidémiologie-Biostatistiques. Bordeaux, France. | pt_BR |
Afiliação | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Afiliação | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil / Hospital Geral de Nova Iguaçu. Nova Iguaçu, RJ, Brasil. | pt_BR |
Afiliação | Hospital Saint-Louis. Assistance Publique-Hôpitaux de Paris. Paris, France. | pt_BR |
Afiliação | Université de Bordeaux. Centre INSERM U897-Epidémiologie-Biostatistiques. Bordeaux, France. | pt_BR |
Afiliação | Université de Bordeaux. Centre INSERM U897-Epidémiologie-Biostatistiques. Bordeaux, France. | pt_BR |
Afiliação | Hospital Saint-Louis. Assistance Publique-Hôpitaux de Paris. Paris, France / University Paris Diderot. Paris, France / 7 INSERM U941. Paris, France. | pt_BR |
Palavras-chave em inglês | HIV | pt_BR |
Palavras-chave em inglês | Pharmacokinetics | pt_BR |
Palavras-chave em inglês | Raltegravir | pt_BR |
Palavras-chave em inglês | Rifampicin | pt_BR |
Palavras-chave em inglês | Tuberculosis | pt_BR |
DeCS | HIV | pt_BR |
DeCS | Tuberculose | pt_BR |
DeCS | Farmacocinética | pt_BR |
DeCS | Raltegravir | pt_BR |
DeCS | Rifampina | pt_BR |
e-ISSN | 1537-6591 | |